Caregivers of care recipients without dementia or disability accounted for the largest absolute number of helpers. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Research
27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
The following strategies helped with implementation of decisions: introducing change slowly; organising legal changes for the carer as well as the patient; involving a professional to persuade the patient to accept services; and emphasising that services optimised, not impeded, independence. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We investigated whether specific SLEs are associated with AD pathology and neurodegeneration and how these associations differ by gender and education. 4 key findings →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Of 57 participants (mean age ± SD = 66.6 ± 7.2 years; female = 52.6%), 38.6% (n = 22) had MCI-level functional impairment and 17.5% (n = 10) had dementia-level functional impairment. 5 key findings →
Design: longitudinal study Participants: 22 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
52/100
Recent guidance from the National Alzheimer's Coordinating Center (NACC) recommends remuneration for all Alzheimer's disease (AD) research participants. 5 key findings →
Design: longitudinal study Participants: 29 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Our study is well placed to evaluate the clinical utility of RMT assessments. 3 key findings →
Participants: 220 Evidence: low
Full summary, score breakdown and related studies → Original source
The results showed that 68.02% of caregivers were highly burdened and 65% exhibited depressive symptoms. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
51/100
Caregiver characteristics and provision of caregiving tasks determine caregiver burden more than care recipient characteristics. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer disease (AD) represents an oncoming epidemic that without an effective treatment promises to exact extraordinary human and financial burdens. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Primary care is the ideal setting for early detection of mild cognitive impairment (MCI) and Alzheimer's disease and related dementias (ADRD), as it serves as the primary point of care for most older adults. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
51/100
As evidence supporting the robustness of blood-based biomarker (BBM) testing for Alzheimer disease (AD) continues to emerge, understanding the perceptions, drivers, and barriers to the adoption of these tests among primary care physicians (PCPs) in the United States is crucial for improving patient outcomes and advancing clinical management of AD. 1 key finding →
Design: cross-sectional Participants: 603 Evidence: low
Full summary, score breakdown and related studies → Original source
Conventional cost estimates, which do not consider unpaid caregiver burden and patient productivity loss, significantly underestimate the total burden of AD. 3 key findings →
Design: modelling Evidence: early
Full summary, score breakdown and related studies → Original source Free full text
We developed and tested the validity of a brief scale to assess everyday functioning in persons with serious mental illness. 3 key findings →
Participants: 434 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Between 2000 and 2017, deaths resulting from stroke, heart disease, and prostate cancer decreased, whereas reported deaths from AD increased 145%.
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Between 2000 and 2015, deaths resulting from stroke, heart disease, and prostate cancer decreased, whereas deaths from AD increased 123%.
Full summary, score breakdown and related studies → Original source Full text may need a subscription
This research, a descriptive qualitative analysis of self-defined serious illness goals, expands the knowledge of what goals are important beyond the physical-making existing disease-specific guidelines more holistic. 5 key findings →
Participants: 160 Evidence: low
Full summary, score breakdown and related studies → Original source
This work suggests that academic and community factors beyond years of education have a marked impact on late-life cognition. 5 key findings →
Participants: 130 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Sensory abilities decline with age. More than 5% of the world's population, approximately 360 million people, have disabling hearing loss. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The increasing ageing global population is causing an upsurge in ailments related to old age, primarily dementia and Alzheimer's disease, frailty, Parkinson's, and cardiovascular disease, but also a general need for general eldercare as well as active and healthy ageing. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
49/100
Due to the ageing population throughout the world, the rates of older adults suffering from dementia are increasing, requiring a closer look at this population. 1 key finding →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
By 2060, ADRD cases in China are projected to reach approximately 49.89 million, with the highest prevalence and economic burden concentrated in provinces such as Shandong, Sichuan, Jiangsu, Henan, and Guangdong. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
A collaborative dementia care program demonstrated significant financial benefit in a managed Medicare population. 4 key findings →
Design: cohort Participants: 242 Evidence: early
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Family caregivers of people with dementia, often called the invisible second patients, are critical to the quality of life of the care recipients. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
TBI had the highest percentage (37%) compared to other conditions, which may be attributed to the prevalent challenge of cognitive impairment in TBI in addition to physical disability. 5 key findings →
Design: cohort study Participants: 2,285 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Dementia is a leading global cause of morbidity and mortality. 2 key findings →
Participants: 15 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →